SynthesisJournal of cachexia, sarcopenia and muscle2023
High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.
Synthesis in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Trial
- A nomogram based on body composition and the prognostic nutritional index to predict early postoperative complications of colorectal cancer.BMC medical imaging · 2026Article
- A nutrition-focused model for predicting postoperative complications in locally advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.BMC gastroenterology · 2026Article
- Article
- A nomogram including body composition parameters for predicting recurrence of pT1 clear cell renal cell carcinoma: a multicenter retrospective study.Insights into imaging · 2026Article
- UsingEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Integrative deep learning analysis of 2D and 3D body composition features for predicting postoperative pancreatic fistula after distal pancreatectomy.Annals of medicine · 2025Article
- Artificial Intelligence-Derived Intramuscular Adipose Tissue Assessment Predicts Perineal Wound Complications Following Abdominoperineal Resection.World journal of surgery · 2025Article
- Article
- Multispectral Optoacoustic Tomography of Skeletal Muscle Unveils Microcirculation and Oxygen Metabolism Alterations in Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- A New Nomogram for Predicting Early Weight Loss Outcomes in Patients with Obesity Following Laparoscopic Sleeve Gastrectomy.Obesity surgery · 2025Article
- Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patients.Journal of translational medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia has been considered an adverse prognostic factor in cancer patients. Intramuscular adipose tissue content, as a new marker of sarcopenia, can effectively reflect skeletal muscle quality. The aim of this study was performed to evaluate the association between high intramuscular adipose tissue content (IMAC) and survival outcomes and postoperative complications in cancer patients. Specific databases, including the Web of Science, Embase and Web of Science, were systematically searched to identify relevant articles evaluating the prognostic value of IMAC in cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were utilized for comprehensive analysis. All data analyses were performed using STATA 12.0 software. A total of 25 studies from 24 articles including 5663 patients were enrolled in the study. Meta-analysis showed that high IMAC was associated with unfavourable overall survival (OS) (HR: 2.21, 95% CI: 1.70-2.86, P < 0.001), relapse-free survival (RFS) (HR: 1.51, 95% CI: 1.30-1.75, P < 0.001) and disease-specific survival (DSS) (HR: 1.64, 95% CI: 1.19-2.28, P = 0.003). Subgroup analysis revealed that high IMAC remained an adverse prognostic factor when stratified by different country, treatment methods, cancer type or analysis type. High IMAC had better predictive value for gallbladder carcinoma (GBC) (HR: 3.50, 95% CI: 1.98-6.17, P < 0.001), hepatocellular carcinoma (HCC) (HR: 1.84, 95% CI: 1.45-2.33, P < 0.001), pancreatic cancer (PC) (HR: 2.11, 95% CI: 1.67-2.66, P < 0.001) and colorectal cancer (CRC) (HR: 2.54, 95% CI: 1.27-5.10, P = 0.009). High IMAC was also identified as a significant risk factor for postoperative complications (OR: 2.05, 95% CI: 1.22-3.46, P = 0.007). High IMAC was associated with an adverse prognosis and an increased risk of postoperative complications in cancer patients. IMAC may be a good indicator of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.